Session 1 – A Fascinating Year of Biotech Innovation and Investment
Date: 24 July (Wednesday) 14:00 - 16:30 Venue: 3F, Bldg. A, CTBC Financial Park, Ballroom A
Dr. Victor Shi is Chairman of the BayHelix Group, a global association of Chinese life science business executives. Since 2017, he is Managing Partner of Serica Capital, focusing on investing in IVD and medical devices in China. Meanwhile, he is Founding President Asia Pacific of QIAGEN, a leading player of In-Vitro diagnostics and life science research service provider home and abroad.
Dr. Shi has 25 years’ experience in life science R&D, sales and marketing, business development, and investment. Previously-held positions include Managing Partner, Aura Partners, SVP of Corporate Development, Bridge Pharmaceuticals, VP of Corporate and Business Development, Genospectra (later Panomics) and Director of Asia Operations at A. M. Pappas & Associates. He was also a faculty member at National University of Singapore School of Medicine and a cancer research scientist at Merck & Co.
He is currently Vice Chair of AdvaMed China Board and Chair of its IVD Working Group. Meanwhile, he is Deputy Secretary-General of the Professional Committee of Chinese In-Vitro Diagnostics Industry Association.
Dr. Shi holds Ph.D. and M.S. degrees from the University of Rochester, New York, and a B.S. degree from the University of Science and Technology of China.